Health ❯Medicine ❯Endocrinology ❯GLP-1 Receptor Agonists
New preclinical data presented at ECO25 reveals tirzepatide’s transient energy expenditure boost and semaglutide’s initial metabolic slowdown, with both drugs’ effects reversing after treatment ends.